**Sonnet BioTherapeutics Issues Financial Results for Q4 2024, Reports Progress in Clinical Trials and Business Development**
On February 13, 2025, Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a clinical-stage company focused on developing targeted immunotherapeutic drugs, released a financial report covering the three months ended December 31, 2024. The company highlighted its recent achievements and provided updates on various clinical trials and business development initiatives. In their recent fiscal quarter, Sonnet reported […]
On February 13, 2025, Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a clinical-stage company focused on developing targeted immunotherapeutic drugs, released a financial report covering the three months ended December 31, 2024. The company highlighted its recent achievements and provided updates on various clinical trials and business development initiatives. In their recent fiscal quarter, Sonnet reported […]
